Interim Analysis Suggests Wider-than-expected Dosing Range for IMU-838 to Treat Ulcerative Colitis
News
Interim analysis of a Phase 2 clinical trial that’s investigating IMU-838 in people with ulcerative colitis (UC) suggests a broader dose range than initially anticipated, announced the therapy’s developer, Immunic ... Read more